Why Women Face Twice the Alzheimer's Risk – And What to Do About It

Records for the S&P and NASDAQ, a Micron explosion, and the Dow went its own way.

The quick scan: Tuesday's return from the Memorial Day long weekend was constructive. The S&P 500 and NASDAQ both closed at fresh record highs, driven by a 19% surge in Micron Technology that pushed the chipmaker past $1 trillion in market capitalisation. The Dow slipped, held back by losses in IBM, UnitedHealth and Cisco. The Iran diplomatic situation remains unresolved but the tone over the holiday weekend was cautiously positive – enough to send markets higher on the open and hold the gains through the close.

S&P 500: +0.61%, 7,519.12 – A fresh record close; nine consecutive winning weeks now within reach heading into the back half of the week
Dow Jones: -0.23%, 50,461.68 – The lone decliner; IBM (-2.73%), UnitedHealth (-1.68%) and Cisco (-1.43%) weighed while Goldman Sachs (+1.84%), Honeywell (+1.76%) and Caterpillar (+1.36%) provided partial offset
NASDAQ: +1.19%, 26,656.18 – Another record; Micron's 19% surge – driven by UBS raising its price target with over 100% upside projected – was the session's standout move and carried the broader chip complex higher.

What's driving it: Micron's surge was the headline, but the underlying driver was Iran. Reports over the long weekend suggested the two sides had exchanged revised proposals, and while no deal was confirmed, the tone was described as the most constructive since negotiations began. Oil fell sharply – Brent crude dropped more than 3.6% to $96.53 – which eased the inflation pressure that has been weighing on markets since the April CPI data. Lower oil means lower inflation expectations, which means the Fed rate-hike conversation becomes less urgent. That chain of logic was enough to send the S&P and NASDAQ to records and keep the VIX, despite a slight uptick to 17.01, well below the levels of early May.

Bottom line: The Iran situation is the swing factor for everything that matters to retirees right now – oil, inflation, interest rates, and market direction. A deal that reopens the Strait of Hormuz would be unambiguously positive for portfolios and purchasing power. Tuesday's session suggests markets are beginning to price in that outcome. For L-Plate Retirees, the message remains the same: stay invested, stay diversified, and don't let the daily moves distract from the longer arc.

The Alzheimer's Risk Factor Women Are Still Not Being Told About

The scoop: Two thirds of all Alzheimer's patients are women.

That figure has been sitting in the research literature for decades, largely explained away as a simple consequence of longevity – women live longer, therefore more of them develop the disease. It was a tidy explanation. It was also wrong.

A growing body of research, anchored by the work of neuroscientist Dr Lisa Mosconi at Weill Cornell Medicine and backed by a new $50 million research initiative called CARE – Cutting Alzheimer's Risk through Endocrinology – is building the case that the real driver is hormonal, not demographic. The disparity isn't primarily about how long women live. It's about what happens to their brains when oestrogen levels fall.

A 45-year-old woman, by current estimates, faces roughly twice the lifetime risk of Alzheimer's as a man her age. That gap persists even after controlling for lifespan. Understanding why – and what to do about it – is what this issue is about.

The oestrogen connection

Oestrogen is not simply a reproductive hormone. It supports the energy metabolism of neurons, reduces inflammation, protects against amyloid plaque accumulation, and maintains the health of the hippocampus – the brain region most directly associated with memory.

When oestrogen levels decline during perimenopause and fall sharply at menopause, the brain loses a degree of this protection. Dr Mosconi's research has shown that women at risk for Alzheimer's begin developing amyloid plaques during perimenopause, considerably earlier than previously understood. The biological processes that may eventually lead to Alzheimer's can begin a decade or more before any cognitive symptoms appear.

This is why approximately 60% of midlife women report memory problems during the menopause transition. The data across populations is consistent: in Australia, 61% of people with dementia are women; in Canada, 72%. These are not noise – they are a pattern pointing to a specific biological mechanism.

The APOE4 factor

The picture becomes more complex for women carrying the APOE4 gene variant, the most significant genetic risk factor for late-onset Alzheimer's.

Carrying one copy of APOE4 roughly triples the risk of Alzheimer's for men. For women, it increases the risk by eight to twelve times. The interaction between APOE4 and oestrogen loss appears to be particularly damaging – the hormonal shift amplifies the genetic vulnerability in ways that don't occur to the same degree in men.

Genetic testing for APOE4 is available through a doctor or specialist clinic. It is not a routine test and the result requires careful interpretation – not everyone with the variant develops the disease, and knowing your status raises as many questions as it answers. But for women in their 40s or 50s with a family history of Alzheimer's, understanding their APOE4 status is increasingly considered a meaningful piece of information to have.

The HRT question

If oestrogen loss is a central mechanism, the obvious question is whether hormone replacement therapy offers protection.

The answer is that it might, but timing appears to be everything. Research by Professor Cassandra Szoeke at the University of Melbourne, drawing on thirty years of data from the Women's Healthy Ageing Project, suggests hormone therapy may prevent or delay dementia onset – but only when started close to the onset of menopause, within what researchers call the "critical window." Starting HRT a decade or more after menopause does not carry the same benefit, and some studies suggest it may increase risk at that stage.

This is not a recommendation to start HRT. That decision involves individual health history, cancer risk, and cardiovascular factors that require a doctor who knows you. What it is, is a reason to include cognitive health in any menopause management conversation – not just hot flushes and bone density.

What men need to understand too

A quick note to the men reading this.

Alzheimer's affects you differently but it affects you too. You are less likely to develop the disease, but considerably more likely to become the primary caregiver of someone who does. The emotional, financial, and practical weight of caring for a partner with dementia is one of the most significant retirement risks that almost no financial plan addresses.

Understanding the risk factors for the women in your life – and supporting conversations about brain health as part of routine health management – is not a gender-specific concern. It is a shared one.

The lifestyle factors that apply to everyone

The modifiable risk factors for Alzheimer's overlap with the habits that appear throughout this newsletter: cardiovascular exercise, quality sleep, social connection, and diet.

Physical activity is the most well-evidenced. Aerobic exercise increases blood flow to the brain and promotes new neuron growth in the hippocampus. What protects the heart also protects the brain.

Sleep is the underrated one. The brain's glymphatic system – its waste clearance mechanism – operates primarily during deep sleep and clears amyloid as it goes. Chronic poor sleep accelerates accumulation. Treat it as a cognitive health practice, not just a comfort issue.

Diet quality, particularly a Mediterranean-style pattern, has been associated with reduced Alzheimer's risk through reduced inflammation and better cardiovascular health. Social connection is an independent protective factor – isolation, by contrast, raises risk.

None of these prevents Alzheimer's with certainty. But the evidence suggests they reduce risk meaningfully – and the earlier they're established, the more they compound.

Actionable Takeaways for L-Plate Retirees:

• Women: treat menopause as a brain health event, not just a reproductive one. The research is clear that the hormonal transition of menopause has neurological consequences that go beyond mood and memory fog. If you're approaching or in perimenopause, brain health belongs in the conversation with your GP – alongside bone density, cardiovascular risk, and the other standard items.

• Ask about HRT timing, not just HRT. If you are considering hormone replacement therapy for menopause symptoms, ask your doctor specifically about the critical window and cognitive protection. The evidence points to greatest benefit when HRT is started close to the onset of menopause. This is a nuanced area that requires individual assessment, but the timing question is worth raising.

• Women with a family history of Alzheimer's should consider discussing APOE4 testing with their doctor. Knowing your genetic status doesn't determine your fate, but it changes the conversation about risk management, monitoring, and the interventions most worth prioritising. This is particularly relevant for women in their 40s and 50s, when the intervention window is still open.

• Prioritise sleep as a cognitive health strategy. Poor sleep accelerates amyloid accumulation – one of the biological pathways to Alzheimer's. If your sleep quality is consistently poor, treating it as a cognitive health issue rather than a lifestyle inconvenience changes what you're willing to do about it.

• Do the cardiovascular exercise. Aerobic exercise is the most consistently well-evidenced lifestyle intervention for brain health across the research literature. It doesn't need to be intense – brisk walking, cycling, swimming – but it needs to be regular. The brain and heart share the same circulation, and what protects one tends to protect the other.

• Men: support this conversation actively. If the women in your life haven't been told that menopause has neurological dimensions that warrant proactive management, this issue is worth sharing. Understanding the risk landscape together is more useful than one person managing it alone.

Your Turn:
Before reading today's issue, did you think of menopause primarily as a reproductive transition, or had you already made the connection to brain health and longer-term cognitive risk?
The "critical window" for HRT and cognitive protection is a finding that many women – and their doctors – are still not fully aware of. If you're a woman who went through menopause without this conversation happening, how does that land for you?
For the men reading this: is Alzheimer's caregiving a scenario you've thought about as part of your retirement planning – and if not, what would it take to start that conversation?

👉 Hit reply and share your thoughts – your answers could inspire fellow readers in future issues.

Writing this takes considerably more time than drinking coffee. If you'd like to help balance that equation, consider shouting L-Plate Retiree a coffee on Ko-fi.